PD-L1 testing by immunohistochemistry in immuno-oncology
Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. However, only ~30% of patients benefit from immune checkpoint inhibitors. Tu...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2023-01-01
|
| coleção: | Biomolecules & Biomedicine |
| Assuntos: | |
| Acesso em linha: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/7953 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|